Is the Cytokinetics (CYTK) investment thesis intact?

Yes. Readouts currently rates the Cytokinetics Thesis Intact. MYQORZO is approved in five markets; FDA rules on its MAPLE-HCM label November 14.

What is the next catalyst for Cytokinetics (CYTK)?

The next dated event is the FDA decision on Aficamten (supplemental application), on Nov 14, 2026, as stated by the company. Also ahead: Enrollment complete (AMBER-HFpEF) for Ulacamten, expected Q4 2026.

How long will Cytokinetics' cash last?

Cytokinetics has said its cash will fund operations beyond Aug 2027 (guidance as of August 6, 2026).

CYTKCytokinetics, Incorporated

⚡

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire · Nov 4, 9:00 PM

Market reactionShares fell 13% on Nov 5.

IntactLast material event Oct 19, 2026 · Updated Oct 26, 2026

MYQORZO is approved in five markets; FDA rules on its MAPLE-HCM label November 14

Cytokinetics sells MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy in the U.S., EU, China, UK and Canada and is seeking approval in non-obstructive HCM.

MYQORZO treats obstructive hypertrophic cardiomyopathy and is approved in five markets. It sold $25.3 million in the second quarter, and about 1,500 patients had received it by June 30. FDA decides by November 14, 2026 on adding MAPLE-HCM data, where it beat metoprolol. In non-obstructive HCM, ACACIA-HCM met both primary endpoints, with a filing planned this quarter. Cytokinetics is suing to invalidate a BMS patent and held about $1.7 billion.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

Non-obstructive HCM filing proceedsAwaiting evidencesNDA submission and acceptance.Next: sNDA submission and acceptance.

Why it is in this state

The evidence, what would weaken it and the source filing

MAPLE-HCM label update approvedAwaiting evidenceFDA action by November 14.Next: FDA action by November 14.

Why it is in this state

The evidence, what would weaken it and the source filing

Launch keeps buildingSupportedQuarterly sales.Next: Quarterly sales.

Why it is in this state

The evidence, what would weaken it and the source filing

Patent case does not block salesSupportedCourt rulings.Next: Court rulings.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Non-obstructive HCM sNDA submission

Tests: Non-obstructive HCM filing proceeds

Fourth quarter of 2026 (company)

Does Cytokinetics file the non-obstructive HCM application on time and does FDA accept it?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentRegulatory

+2.1%Oct 19, 2026

MYQORZO is approved in five markets; FDA rules on its MAPLE-HCM label November 14

IntactClinical

-1.9%Oct 12, 2026

MYQORZO approved in US, EU, and UK with a second indication filing in; commercial ramp and nHCM sNDA decision determine how far the franchise grows

IntactClinical

-7.5%Aug 28, 2026

MYQORZO approved in US, EU, and UK with Phase 3 wins in two HCM subtypes; commercial ramp and BMS patent litigation are the tests

IntactCommercial

-5.7%Aug 6, 2026

MYQORZO approved and generating revenue across US, EU, and China; label expansion to non-obstructive HCM hinges on Nov 2026 FDA decision

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Obstructive HCM

aficamten · 2 upcoming · 5 completed

PDUFA Decision

Nov 14, 2026

Commercial LaunchEU

H1 2027

HFpEF· LVEF ≥60%

ulacamten · 1 upcoming

Enrollment: CompletionAMBER-HFpEF

2H 2025Q4 2026

Non-obstructive HCM

aficamten · 2 upcoming · 1 completed

Regulatory Submission

Q4 2026

Regulatory SubmissionEU

early 2027

Obstructive HCM· pediatric

aficamten · 1 upcoming · 1 completed

Phase 3 Data: ToplineCEDAR-HCM

early 2027

HFrEF

omecamtiv mecarbil · 1 upcoming

Phase 3 Enrollment: CompletionCOMET-HF

2027

Obstructive HCM· Japan

aficamten · 1 completed

CAMELLIA-HCM trial completion ( , Japan; Bayer)Japan

Reported Nov 4, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Cytokinetics (CYTK) investment thesis intact?: Yes. Readouts currently rates the Cytokinetics Thesis Intact. MYQORZO is approved in five markets; FDA rules on its MAPLE-HCM label November 14.
What is the next catalyst for Cytokinetics (CYTK)?: The next dated event is the FDA decision on Aficamten (supplemental application), on Nov 14, 2026, as stated by the company. Also ahead: Enrollment complete (AMBER-HFpEF) for Ulacamten, expected Q4 2026.
How long will Cytokinetics' cash last?: Cytokinetics has said its cash will fund operations beyond Aug 2027 (guidance as of August 6, 2026).

Other companies we cover in these diseases

Heart failure with preserved ejection fraction: Edgewise Therapeutics (EWTX)Tenax Therapeutics (TENX)
Heart failure with reduced ejection fraction: Mesoblast (MESO)
Hypertrophic cardiomyopathy: Lexeo Therapeutics (LXEO)

Drug pages: Aficamten
Disease areas: Neuromuscular diseases, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

4 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.